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ABSTRACT
Breast carcinoma is a major health issue for millions of women. Current therapies 
have serious side effects, and are only partially effective in patients with metastatic 
tumors. Thus, the need for novel and less toxic therapies is urgent. Moreover, hormonal 
and antibody therapies effective in other subtypes are not effective in Triple Negative 
Breast Cancer (TNBC). Immunotherapeutic strategies directed against specific tumor-
associated antigens (TAAs) and mediated by specific cytotoxic T lymphocytes (CTL) 
have been largely underexplored in this disease. Cancer-testis antigens (CTA) are a 
group of TAAs displaying the ideal characteristics of promising vaccine targets, i.e. 
strong immunogenicity and cancer specificity. The CTA, Sperm Protein 17 (SP17), has 
been found to be aberrantly expressed in different neoplasms, including ovarian and 
esophageal cancers, nervous system tumors and multiple myeloma, and has been 
suggested as a candidate target for immunotherapy.
Here, we evaluated SP17 expression levels in breast cancer cell lines, invasive 
ductal breast carcinoma, including patients with TNBC, and adjacent non-neoplastic 
breast tissue, and determined whether SP17 was capable of generating SP17-specific 
cytotoxic T lymphocytes in vitro.
We showed that SP17 is expressed in breast cancer cell lines and primary breast 
tumors and importantly in TNBC subtype, but not in adjacent non-tumoral breast 
tissue or unaffected tissues, except in male germinal cells. Furthermore, we detected 
specific anti-SP17 antibodies in patients’ sera and we generated SP17-specific, HLA 
class I-restricted, cytotoxic T lymphocytes capable of efficiently killing breast cancer 
cells.
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 43), pp: 74378-74390
                                                               Research Paper
Oncotarget74379www.impactjournals.com/oncotarget
INTRODUCTION
The American Cancer Society estimates that 
approximately 252,710 new cases of female breast 
cancer (BC) will be diagnosed with and 40,610 women 
will die from BC in 2017. Available systemic treatment 
options for BC, including targeted therapies such as those 
hormone-based or anti-Her-2/Neu antibodies, as well as 
standard cytotoxic antineoplastic agents, have proven 
effective in many patients afflicted with this disease [1–4]. 
Unfortunately, BC is far from being considered a complete 
curable disease. Metastatic and relapsed BC remain  fatal. 
A sub-type of BC, namely triple negative breast cancer 
(TNBC) [5] is negative for estrogen and progesterone 
receptor (ER, PR) and HER-2/neu. Hence, the hormonal 
and molecular therapies used in other breast cancer 
subtypes are not effective. These relatively effective 
interventions are plagued by their related side effects (i.e., 
myelosuppression, cardiotoxicity, osteopenia) and their 
inability to cure patients with advanced stage BC and/or 
intrinsically or acquired resistant disease [6–12]. These 
factors underline the urgent need for novel therapeutic 
strategies.
There have been major advances in understanding 
the underlying molecular basis of BC over the last 
20 years, leading to significant improvement in the 
design of novel therapeutic strategies for this disease. 
Nevertheless, only a few of those strategies have focused 
on the discovery of new targets and therapeutic treatments 
that exploit the activation of cellular immunity against 
BC. Such immunotherapeutic approaches would take 
advantage of specific BC-associated antigens capable of 
eliciting strong and specific cytotoxic T lymphocyte (CTL) 
antitumor responses. Despite the sound rationale and 
promise of such a strategy, BC specific immunotherapy 
has only recently been explored in both animal models and 
the clinical setting [13–15].
Immunotherapies based on the discovery of BC-
specific antigens present significant advantages over 
traditional BC treatments such as ease of administration, 
limited toxicity and high specificity against cancer cells. 
To date, a number of antigens have been tested as potential 
targets for BC vaccines in animal models and some have 
been tested in the clinical setting with variable results [13, 
16–28]. The main caveats of these interventions have been 
the suboptimal specificity for BC cells, tissue distribution 
and weak immunogenicity of the antigens tested.
More recently, a novel and expanding group of 
tumor-associated antigens (TAAs), known as cancer/testis 
antigens (CTAs), has raised interest as a potential target 
for cancer immunotherapy [29–31]. CTA expression was 
thought to be testis-restricted but several studies have 
shown significant expression in cancer tissues, as opposed 
to their non-tumoral counterparts, suggesting a strong 
association between their expression and the neoplastic 
phenotype [32–34]. Another important characteristic of 
CTAs is their marked immunogenicity. This, coupled with 
their restricted expression in male and female germinal 
cells and neoplastic tissues, make these molecules ideal 
candidates for immunotherapeutic targeting. CTA-based 
immunotherapies have been tested in animal models of 
neoplasia as well as cancer patients with variable results 
[35–37]. Interestingly, CTA expression in BC has been 
found to affect cell proliferation and to correlate with a 
lack of estrogen receptor expression and poor prognosis 
making these molecules very attractive therapeutic targets 
[18, 38–40].
The CTA Sperm Protein 17 (SP17) is a highly-
conserved mammalian protein, normally found in 
germinal cells, where it contributes to sperm maturation, 
capacitation and acrosome reaction [41–43]. Aberrant 
SP17 expression has been shown in ovarian and 
esophageal cancers, nervous system tumors, multiple 
myeloma and esthesioneuroblastoma [44–48]. Although 
SP17 mechanisms of action in cancer cells are still poorly 
understood, it has been shown that SP17 mediates cell-cell 
adhesion in malignant B-lymphocytes through heparan-
sulfate and enhances cell motility and drug resistance in 
ovarian cancer and esophageal cancer cells [49–51]. Thus, 
the development of SP17-targeted immunotherapy may 
not only generate antitumor cellular immunity capable 
of cancer cell eradication, but also would interfere with 
fundamental mechanisms involved in cancer cell survival, 
metastasis and drug resistance mediated by SP17.
To our best knowledge, SP17 expression and 
potential as an immunotherapeutic target in BC has not 
been previously investigated. In this study, we evaluated 
SP17 expression in human breast cancer cell lines, 
primary female BC, including TNBC, and adjacent 
unaffected breast tissues. Additionally, we assessed SP17 
immunogenicity in terms of eliciting an antibody response 
in patients and a cytotoxic response ex vivo. Our findings 
will serve as “proof of concept” for the future development 
of SP17 as a BC biomarker and immunotherapeutic target 
in this disease.
RESULTS
First, we analyzed SP17 mRNA expression in 
infiltrating ductal breast cancer (IDBC) cell lines. 
We detected SP17 mRNA in IDBC cell lines, namely 
HCC1187, HCC70, BT20, MC-F7, and MDA-MB-231. 
As shown in Figure 1, HCC1187, HCC70, MC-F7 and 
MDA-MB-231 displayed higher level of SP17 mRNA 
expression, compared with BT20. Further, we showed 
that SP17 mRNA expression was undetectable in a panel 
of human normal tissues, including the normal mammary 
duct (Figure 2). We validated our data by analyzing 
SP17 expression at the protein level in HCC1187, 
HCC70, BT20, MC-F7, and MDA-MB-231 cell lines 
by flow cytometry. As shown in Figure 3, SP17 protein 
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was expressed in all IDBC cell lines at different levels. 
Specifically, HCC1187, HCC70 and MC-F7 showed 
an expression close to 100% (99%, 97% and 93% 
respectively), while 79% of BT20 and 84% of MDA-
MB-231 cells were SP17+. The MFI values obtained with 
flow cytometry (Figure 3) correlated with the intensity of 
the PCR products shown in Figure 1.
Figure 4A shows the expression of SP17 in 
spermatozoa collected from healthy human volunteers, and 
in unaffected testicular biopsies sampled in male subjects 
for diagnostic purposes (Figure 4C and 4D). Adjacent non-
tumoral breast tissue was found immunonegative for SP17 
(Figure 5A and 5B). In contrast, SP17 has been found 
in infiltrative ductal breast cancers (Figure 5C and 5D), 
including TNBC (Figure 5E and 5F).
To evaluate the suitability of SP17 as a target for BC 
immunotherapy, we determined the presence of anti-SP17 
antibodies in the serum of patients and healthy controls by 
ELISA (Figure 6). One-way ANOVA and Dunn's multiple 
comparisons test showed that the differences in OD values 
Figure 1: RT-PCR for SP17 in BC cell lines HCC1187, HCC70, BT20, MC-F7, and MDA-MB-231. A reaction without 
cDNA template (no temp) and with RT reaction performed without retro-transcriptase (no RT) were included as negative controls (not 
shown). β-ACT expression was used as an internal control.
Figure 2: Analysis of SP17 expression in the indicated normal tissues and cancer cell lines. Results represents the mean 
values of the 2-ΔCt calculated out of 3 experiments. Among non-tumoral human tissues, only testis and epididymis showed significant SP17 
mRNA expression.
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Figure 3: Flow-cytometry analysis for SP17 in (A) HCC1187; (B) HCC70; (C) BT20; (D) MC-F7; (E) MDA-MB-231; (F) non-tumoral 
human PBMCs (Lonza, Allendale, NJ, USA). After permeabilization as indicated in Materials and Methods, cells were incubated with 
anti-SP17 mouse monoclonal antibody or with the corresponding isotype control. Results are depicted as the FSC scatter versus FL-1 
fluorescence. Vertical bars represent the fluorescent threshold measured on the respective isotype controls.
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between HC and tumor groups were significant (p=0.0225 
for BC, and p=0.0221 for TNBC). Table 2 summarizes the 
results from IHC and ELISA.
Autologous SP17-stimulated T-cells were able 
to specifically kill IDBC cells derived from patients’ 
primary samples (Figure 7). To determine the SP17-
specificity of cell lysis, we measured T-cell-mediated 
killing of autologous LCL, pulsed with HPV-E6 antigen 
or with SP17. Results (Figure 7) show that significant 
lysis is detectable only in SP17-expressing target cells, 
namely LCL-SP17. We also proved that SP17-stimulated 
T-cells were unable to kill LCL-SP17 targets when HLA-I 
molecules were blocked through a specific antibody, while 
killing activity was not affected by HLA-II blocking 
(Figure 7).
DISCUSSION
Our findings demonstrated, for the first time, the 
expression of the CTA SP17 in BC cell lines and primary 
BC cells, including TNBC. We showed that SP17 is 
expressed at both mRNA and protein levels in BC cell 
lines. Importantly, SP17 is expressed in BC cell lines 
derived from both primary (HCC70, HCC1187, BT20) and 
metastatic (MDA-MB-231 and MC-F7) BC, indicating 
that it is conserved during the metastatic process. SP17 
expression in metastatic sites is relevant since the 5-year 
survival rate of patients drops from 98% if diagnosed with 
localized malignancy to 27% when they are diagnosed 
with metastatic disease (http://seer.cancer.gov/statfacts/
html/breast.html, SEER 18 2007-2013 data). Moreover, 
we have demonstrated the presence of SP17 protein in 
Figure 4: SP17 protein expression in ejaculated spermatozoa and testicular biopsy tissues. (A) SP17 was found in ejaculated 
spermatozoa collected from healthy human donors. (A) SP17 was localized abundantly throughout the principal piece of the tail (objective 
magnification 40x). (B) The IgG controls were always negative (objective magnification 40x). SP17 was also found in human testicular 
biopsies (C-D). SP17 was localized in the cytoplasm of some spermatocytes and that of early and late spermatids (objective magnification 
40x). Although spermatogonia and Sertoli cells were not labeled, some non-apoptotic spermatocytes and elongated spermatids were 
immunopositive.
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BC tissues, including TNBC, but not in adjacent non-
tumoral breast tissues, suggesting the specificity of SP17 
expression in BC. The specificity of SP17 expression in 
cancer (aside from its expression in testes) was further 
supported by the lack of SP17 expression in a wide panel 
of human healthy tissues, including mammary ducts, as 
displayed by quantitative RT-PCR.
The current gap that exists in the immunotherapy 
of BC is the discovery of novel tumor-associated antigens 
that would allow the development of BC-specific tumor 
vaccines. Interestingly, SP17 expression has recently 
been linked to the development of drug resistance in 
both ovarian carcinoma and esophageal squamous cancer 
cell lines, indicating this CTA as a potential marker for 
disease progression and risk of drug resistance in these 
neoplasms [49, 51]. Moreover, SP17 restricted expression 
in tumor cells makes it an ideal target for developing 
new and more effective immunotherapeutic strategies, as 
Figure 5: SP17 protein expression in IDBC and TNBC tissues. Adjacent non-tumoral breast tissue was found immunonegative 
for SP17 at low as well as high magnification (A, objective magnification 20x; B, objective magnification 20x). In contrast, SP17 has been 
found in infiltrative ductal breast cancers (C, objective magnification 20x; D, objective magnification 40x), including TNBC (E, objective 
magnification 20x; F, objective magnification 40x).
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previously shown in ovarian cancer and multiple myeloma 
models [52–54]. The possibility to establish SP17-directed 
immunotherapies is especially relevant in TNBC, where 
the widely used antibody, Herceptin [55], is not effective 
due to the lack of its target, Her-2/Neu [56]. Thus, we 
evaluated SP17 immunogenicity in BC patients, including 
TNBC cases.
To this goal, we searched for circulating anti-
SP17 antibodies in the serum of BC patients and healthy 
controls. We detected significant levels of anti-SP17 
antibodies specifically in the serum of BC patients, 
demonstrating its immunogenicity in vivo. SP17 
antibodies were present also in the TNBC sub-group of 
patients. Finally, we were able to generate autologous 
SP17-specific T-cells in vitro, which efficiently killed 
autologous tumors, in a SP17- and HLA-I-specific 
manner. Due to the tumor-selective expression of SP17, 
this finding indicates that SP17-based therapeutic vaccines 
are expected to have minimal toxicities. Immunotherapy 
is especially and dramatically needed in TNBC. This sub-
type lacks estrogen receptor (ER), progesterone receptor 
(PR) and epidermal growth factor receptor-2 (Her-2/Neu). 
As such, it cannot be treated with drugs like tamoxifen or 
trastuzumab, which specifically target hormone receptors 
Figure 6: ELISA showed the presence of IgG anti-SP17 in 10/22 BC patients (~45%) and in 5/6 TNBC patients. The 
right-sided reference interval (OD=0.17, dotted line) was calculated in accordance to the Clinical and Laboratory Standards Institute’s 
(CLSI) guidelines [64], using MedCalc software. *, one-way ANOVA and Dunn's multiple comparisons test p<0.05.
Table 1: BC cell lines characteristics
ATCC # Histology Tumor source TNBC (yes/no)
HCC70 CRL-2315 Primary ductal carcinoma Primary Yes
HCC1187 CRL-2322 Primary ductal carcinoma Primary Yes
BT20 HTB-19 Carcinoma Primary Yes
MDA-MB-231 HTB-26 Adenocarcinoma Metastasis, pleural effusion Yes
MC-F7 HTB-22 Adenocarcinoma Metastatic site, pleural effusion No
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or Her-2/Neu. In addition, TNBC is characterized by high 
recurrence rate and poor prognosis [56]. To date, little 
progress has been done in the discovery and validation 
of alternative targets in TNBC. Specifically, MUC1 [57], 
VEGFR-2 [58], and androgen receptor [59] have been 
proposed as TNBC targets. Although our study was 
partially limited to a restricted number of patients and 
the actual prevalence of SP17 expression in TNBC could 
not be assessed, SP17 might be a more promising antigen 
for future therapeutic TNBC vaccine due to its more 
specific expression in tumor cells, compared to the other 
aforementioned potential targets.
Our findings support the potential of SP17 as a 
promising novel target for BC, similarly to what we 
have previously demonstrated in an animal model 
of ovarian cancer [52, 60]. These results open the 
door for the development of innovative, SP17-based 
immunotherapeutic strategies that may overcome the 
limitations of available therapies and offer a personalized 
approach to patients with BC.
Table 2: Samples included in this study and summary of IHC and ELISA results
Number Median age (range) SP17 positive by IHC (N of analyzed samples)
Anti-SP17 IgG 
positive (N of analyzed 
samples)
Healthy controls 
(unaffected adjacent breast 
tissue)
7 40 (18-66) 0 (7) 0 (6)
IDBC 22 48 (34-62) 10 (22) 9 (22)
TNBC 36 50 (38-70) 17 (36) 5 (6)
All BC combined 58 48 (34-70) 27 (58) 14 (28)
Figure 7: Patients’ CTLs kill autologous tumors in a SP17 and HLA-I restricted manner. CTLs generated from 10 BC 
patients were able to kill autologous BC cells. Experiments were performed in triplicate. Results represent the mean and range values of 
specific lysis. CTLs were able to kill autologous lymphoblastoid cells (LCL) pulsed with SP17 (LCL-SP17) but not with the unrelated 
antigen, HPV16-E6 (LCL-E6). Target cell lysis was inhibited by a blocking antibody directed at HLA class I molecules but not HLA class 
II molecules (HLA-I blockade and HLA-II blockade, respectively). Mann–Whitney U test was performed to assess statistical significance 
(α=0.05): ***, p≤0.001; n.s.= not significant.
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MATERIALS AND METHODS
Cell lines and primary samples
TNBC cell lines were purchased from the 
American Type Culture Collection (ATCC, www.atcc.
org) and maintained at 37°C with 5% CO2 in the complete 
mediums recommended by ATCC. Table 1 summarizes the 
characteristics of the cell lines used in this study. HCC70 
cells (ATCC No. CRL-2315) were derived from a primary 
ductal carcinoma; HCC1187 (ATCC No. CRL-2322) were 
derived from an invasive ductal carcinoma; BT20 (ATCC 
No. HTB-19), MDA-MB-231 (ATCC No. CRM-HTB-26) 
and MC-F7 (ATCC No. HTB-22) were derived from 
metastatic site. Cell lines were analyzed in 2 passages after 
purchasing, to rule out possible alterations due to in vitro 
propagation.
A series of consecutive patients with IDBC 
who underwent surgical treatment and follow-up at 
the Humanitas Research Hospital, Rozzano, Milan, 
Italy, were retrospectively collected. For each patient, 
the histological grade, pathological stage, ER and PR 
receptors status, HER-2/new, MIB-1 and the number 
of positive lymph nodes were known. TNBC samples 
were from the Department of Internal Medicine, Texas 
Tech University Health Sciences Center (Amarillo, TX, 
USA). The study was carried out in accordance with 
the guidelines of the Ethics Committee of the hospital 
treating the patients, all of whom were fully informed of 
the possible discomfort and risks of surgical treatment. 
Table 2 summarizes the characteristics of the subjects 
included in the study.
RNA isolation and RT-PCR
Total RNA was isolated from TNBC cell lines through 
the RNAqueous® Total RNA isolation Kit (Ambion, Austin, 
TX) and 1 μg was reverse-transcribed using the M-MLV 
Reverse Transcriptase Kit (Sigma-Aldrich, Saint Louis, 
MO). RNAs from normal human tissues were obtained from 
FirstChoice® Total RNA (Ambion, Austin, TX). 1/20 of 
retro-transcription reaction volume was PCR-amplified in 20 
μL reaction with PCR Core kit with Taq DNA polymerase 
(Sigma-Aldrich, Saint Louis, MO). Primers sequences 
were: SP17 left 5’-GCTCGGAGAGAAAGGAGGTTC-3’, 
SP17 right 5’-TACTCCCCCATTCTGCTGGA-3’, Human 
β-actin Real-Time Primer Mix (1 nmol/200 μL, Origene cat. 
# HP204660).
All reactions were performed at 57°C annealing 
temperature for 38 cycles with 2 mM MgCl2. 10 μL PCR 
reaction were run in 2% w/v agarose gel stained with 
ethidium bromide. Pictures were taken after 30 minutes 
run using the Molecular Imager ChemiDoc XRS+ System 
(Bio-Rad) equipped with a Quantity One 1-D Analysis 
Software (Bio-Rad). Quantitative RT-PCR was performed 
as previously described [33, 61].
Flow cytometry
400,000 cells were washed with PBS 1X and 
fixed with buffered paraformaldehyde (4% W/V in PBS, 
pH=7.4). After 5-min permeabilization on ice with BD 
cytofix/Cytoperm (BD Biosciences, San Diego, CA), cells 
were incubated with the anti-SP17 mouse monoclonal 
antibody that we have previously described [62]. Negative 
controls were cells incubated with equal amounts of 
appropriate itsotype control antibody. After 1-h incubation 
on ice, cells were washed three times in BD Perm/Wash 
buffer (10X in H2O, BD Bioscience, San Diego, CA), and 
then incubated on ice (30 minutes) with AlexaFluor®488 
donkey anti-mouse IgG (H+L) (Life technologies, USA). 
Following 3 washing steps with BD Perm/Wash buffer, 
cells were re-suspended in PBS and analyzed using a 
FC500 flow-cytometer (Beckman Coulter).
Immunocytochemistry
To investigate the immunocytochemical expression 
of SP17, washed spermatozoa collected from human 
healthy volunteers donors, were cytocentrifuged for 1 min 
at 800 rpm on a glass slide using a Cytospin-2 centrifuge 
and then fixed with Biofix (Bio-Optica; Milan, Italy). The 
cells were permeabilized with 0.5% Triton X-100 (Sigma), 
0.1% sodium citrate in PBS at 4C for 15 min, followed 
by treatment with either a primary antibody raised 
against SP17 at RT for 2 hours or with 1 μg/ml mouse 
IgG1 (DAKO) as a negative control. This was followed 
by 30-min incubation with the DAKO Envision System. 
3, 3’-diaminobenzidine tetrahydrochloride (Dako) was 
used as a chromogen to yield brown reaction products. 
The nuclei were lightly counterstained with hematoxylin 
solution.
Immunohistochemistry
2 μm thick-sections were cut from formalin-
fixed and paraffin-embedded surgical BC or testicular 
biopsy tissue and processed for immunohistochemistry. 
In brief, after deparaffining and rehydration, they were 
immersed in an antigen retrieval bath (Dako, Milan, 
Italy), incubated with 3% H2O2 for 15 minutes to quench 
endogenous peroxidase activity, treated for two hours at 
room temperature with primary antibodies raised against 
SP17, or with rabbit IgG (Dako) as a negative control, and 
then incubated for 30 minutes with the DAKO Envision 
system (Dako). 3, 3’-diaminobenzidine tetrahydrochloride 
(Dako) was used as a chromogen to yield brown reaction 
products. The nuclei were lightly counterstained with 
hematoxylin solution.
Enzyme-linked immunosorbent assay
An enzyme-linked immunosorbent assay (ELISA) 
was performed on the sera of BC patients and of  healthy 
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donors. Polystyrene 96-well flat-bottom plates were 
coated with 5μg/μL SP17 recombinant protein (generated 
in our laboratory) and incubated overnight at 4 °C. After 
washing and blocking with SuperBlock® buffer (Pierce, 
Rockford, IL, USA), plates were placed at 37 °C for 2 
hours. Each sample, as well as the negative controls 
(PBS supplemented with 10% FBS), were diluted 1:1000 
in SuperBlock® buffer and incubated for 4 hours at RT. 
After washing with PBS/0.05% Tween-20, horseradish 
peroxidase-conjugated goat anti-human IgG (Pierce), 
diluted 1:5000 in SuperBlock®, was added and allowed 
to incubate at RT for 2 hours. After washing 3 times with 
PBS/0.05% Tween-20, the 1-Step Ultra TMB-ELISA 
chromogenic substrate (Pierce) was added to each well 
for color development for 10 minutes. After blocking the 
reaction with sulfuric acid, the intensity was measured by 
the Victor2 micro-plate reader (PerkinElmer, Waltham, 
MA, USA) at 450 nm wavelength excitation. All samples 
were run in triplicate.
Isolation of peripheral blood mononuclear cells 
and generation of dendritic cells
Peripheral blood mononuclear cells (PBMCs) were 
prepared by separation of heparinized blood with density 
gradient centrifugation performed with Ficoll-Hypaque. 
PBMCs were seeded into 6-well culture plates with 3 mL 
RPMI 1640 at the density of 8-10X106 cells/well. After 2 
hours incubation at 37°C and 5% CO2, non-adherent cells 
were removed; adherent cells were maintained in RPMI 1640 
supplemented with 10% FBS, 103 IU/mL interleukin 4 (IL-4) 
and 800 IU/mL granulocyte-macrophage colony-stimulating 
factor (GM-CSF). After 1-week culture, dendritic cells (DCs) 
were harvested and pulsed with SP17 protein [53, 54].
DC pulsing
DCs were washed twice with PBS and transferred 
in a 50 mL polypropylene tube. The recombinant SP17 
protein (rSP17) was generated in our laboratory [55] and 
mixed with the cationic lipid DOTAP (Roche, Mannheim, 
Germany) at room temperature for 20 minutes, then added 
to the DCs for 3 hours at 37°C.
Generation of SP17-specific CTLs in vitro
Antigen pulsed DCs were co-cultured with fresh 
autologous PBMCs at a ratio of 1:10 in RPMI 1640 with 
2% autologous serum, 10 IU/mL IL-2 and 5 ng/mL IL-
7. Irradiated autologous PBMCs feeder cells and SP17 
protein (50 μg/mL) were added every 7 days, while IL-2 
was added every 3 days [53, 54].
Cytotoxicity assay
A standard 4-hour LDH release cytotoxicity assay 
(LDH Release Assay Kit, Promega, USA) was performed 
to evaluate the cytotoxic activity of the SP17-stimulated 
T cells. Cytotoxicity against autologous breast cancer 
primary cells was determined at various effector:target 
cell ratios. For the measurement of CTL-mediated lysis of 
autologous lymphoblastoid cells (LCL) pulsed with SP17 
or HPV16-E6 antigen, cytotoxicity assay was performed 
with 20:1 effector:target ratio. LCL were generated from 
autologous PBMCs as described previously [63]. To 
determine HLA restricted response, a cytotoxicity assay 
was performed with or without 25 μg/mL HLA-I or HLA-
II (W6/32 or L243 monoclonal antibody, respectively, 
BioLegend 11080 Roselle Street, San Diego, CA) blocking 
antibodies (effector:target ratio 20:1).
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